$CASIF News

What Drove CASI Pharmaceuticals' 24% Rise After Hours?

CASI Pharmaceuticals shares are trading lower after the company announced receipt of delisting decision from the Nasdaq.

Dow Jumps 200 Points; Lowe's Issues Weak Earnings Outlook

CASI Pharmaceuticals To Be Delisted From Nasdaq, Effective Feb. 26

CASI Pharmaceuticals Fails To Renew FOLOTYN Import License In China, Halting Sales

Are Medical Stocks Lagging Alkermes (ALKS) This Year?

CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

CASI Pharmaceuticals Gets China National Medical Products Administration's Approval To Start Phase1/2 Clinical Study For CID-103 In Adults With Chronic Active Renal Allograft Antibody-Mediated Rejection

12 Health Care Stocks Moving In Wednesday's After-Market Session

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7

CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

CASI stock has given up its prior gain. CASI Pharmaceuticals shares were trading higher after the company announced it received an extension to regain Nasdaq compliance.

CASI Pharmaceuticals shares are trading higher after the company announced it received an extension to regain Nasdaq compliance.

CASI Pharmaceuticals Granted Extension Through February 17, 2026 To Regain Nasdaq Compliance

CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

CASI Pharmaceuticals Secures $20M Convertible Note Investment To Fund Phase 1 Renal Transplant Study In China

CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

CASI Pharmaceuticals Highlights Results From CID-103 Immune Thrombocytopenia Study Study At Annual ASH Meeting

CASI Pharmaceuticals Announces Changes in Board Governance